MVR0.F Medivir AB (publ)
- Market cap
- EUR 50.7M
- P/E
- -
- P/B
- 2.18x
- ROE
- -20.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MVR0.F undervalued?
Graham numberThe Graham number of Medivir AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medivir AB (publ) fundamental analysis
No fundamental analysis for Medivir AB (publ) yet.
Medivir AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone d…
Full company profileMedivir AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medivir AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 25.5M | 4.41M | 7.63M | 3.48M | 8.51M | 3.87M |
| Operating Income | -64.4M | -88.6M | -92.8M | -128M | -93.0M | -64.0M |
| EBITDA | - | -85.3M | -85.7M | -120M | -59.5M | -61.3M |
| Net Income | -63.1M | -88.8M | -89.3M | -123M | -94.4M | -60.7M |
| EPS | -0.93 | -1.31 | -0.85 | -1.10 | -0.21 | -0.10 |
| Balance Sheet | ||||||
| Total Assets | 336M | 234M | 288M | 173M | 306M | 326M |
| Total Liabilities | 54.7M | 41.4M | 70.0M | 57.1M | 41.9M | 36.7M |
| Shareholders' Equity | 281M | 193M | 218M | 116M | 265M | 290M |
| Cash & Short-term Investments | 14.7M | 6.45M | 25.6M | 10.8M | 31.9M | 7.60M |
| Cash Flow | ||||||
| Operating Cash Flow | -48.7M | -102M | -59.7M | -124M | -73.3M | -61.3M |
| Capital Expenditure | 0.00 | 382K | 261K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -48.7M | -102M | -59.9M | -124M | -73.3M | -61.3M |
| Ratios | ||||||
| ROE | -22.5% | -46.0% | -41.0% | -106.8% | -35.7% | -20.9% |
| ROA | -18.8% | -37.9% | -31.0% | -71.5% | -30.8% | -18.6% |
| Net Profit Margin | -247.2% | -2,013.7% | -1,170.1% | -3,539.5% | -1,109.8% | -1,569.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Medivir AB (publ) dividends
Medivir AB (publ) has not paid dividends in the last 5 fiscal years.
Who owns Medivir AB (publ)
- Insiders 36.17%
- Institutions 15.39%
- Public & others 48.44%
- Shares outstanding 624M
- Free float 349M
Medivir AB (publ) company profile
- Company name
- Medivir AB (publ)
- Ticker
- MVR0.F
- ISIN
- SE0020181014
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Lunastigen 5, Huddinge, Sweden, 14122
- Phone
- 46 8 54 68 31 00
- Website
- medivir.com
About Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Medivir AB (publ) management
5- Mr. Jens LindbergChief Executive Officer · born 1971
- Mr. Patrik NorgrenChief Financial Officer · born 1963
- Mr. Fredrik ÖbergChief Scientific Officer · born 1965
- Ms. Pia BaumannChief Medical Officer · born 1966
- Karin TunbladSenior Principal Scientist & MIV-818 Project Leader